Week in Review: BGI Raises $320 Million for Diagnostics Division

BGI Shenzhen, the IVD subsidiary of China’s large genomics sequencing company, raised $320 million by selling a 20% stake to unnamed institutional investors; Fosun Pharma is already in the due diligence stage on several Israeli medical device company acquisitions; the Jackson Lab and Wuhan Frasergen Bioinformatics signed a MOU to build a cancer genetics research facility at Wuhan BioLake; RuiYi announced a mAb research collaboration with the iHuman Institute at ShanghaiTech University; Milestone Scientific formed a joint venture to distribute its medical and dental devices to China; Shuwen Biotech in-licensed China rights to a colorectal cancer test from DiagnoCure of Canada; Steve Yang, now COO of WuXi PharmaTech, told the   ChinaBio® Partnering Conference that WuXi hopes to put its entire R&D platform on the cloud; Omron and NeuroMetrix filed for China approval of a testing device for diabetic peripheral neuropathy; Waters Corporation received CFDA approval for its neonatal metabolites disease screening device; and ScinoPharm Taiwan will supply API from its Changshu facility for a novel stem cell mobilizer discovered by TaiGen Biotech. More details…. Stock Symbols: (SHE: 600196; HK: 02196) (OTCQB: MLSS) (TSX: CUR; OTCQX: DGCRF) (NSYE: WX) (TO: 6645) (NSDQ: NURO) (NYSE: WAT) (TW: 1789) (TW: 4157) Share this with colleagues: // //